IDEXX Laboratories (NASDAQ:IDXX) Shares Cross Above 200-Day Moving Average - Time to Sell?

Key Points

• IDEXX Laboratories shares crossed above their 200-day moving average, trading near $575.98 versus the $574.96 average, with approximately 477,765 shares changing hands.
• Analyst views remain generally positive, with nine Buy ratings and six Holds producing a “Moderate Buy” consensus and an average price target of $727.69. Recent targets ranged from $627 at UBS to $740 at Goldman Sachs.
• The company exceeded quarterly expectations, reporting $4.27 in adjusted EPS and $1.22 billion in revenue, while revenue rose 9.7% year over year; IDEXX also issued fiscal 2026 EPS guidance of $14.69–$14.94.

Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Get Free Report) crossed above its two hundred day moving average during trading on Thursday. The stock has a two hundred day moving average of $574.96 and traded as high as $576.17. IDEXX Laboratories shares last traded at $575.98, with a volume of 477,765 shares changing hands.

Analysts Set New Price Targets

Several analysts have issued reports on IDXX shares. UBS Group cut their price target on shares of IDEXX Laboratories from $670.00 to $627.00 and set a "neutral" rating for the company in a research report on Tuesday. Citigroup boosted their target price on IDEXX Laboratories from $650.00 to $670.00 and gave the company a "neutral" rating in a research note on Wednesday, August 5th. Barclays dropped their target price on IDEXX Laboratories from $800.00 to $710.00 and set an "overweight" rating for the company in a report on Tuesday, August 11th. KeyCorp began coverage on IDEXX Laboratories in a research report on Monday, October 12th. They set a "sector weight" rating on the stock. Finally, The Goldman Sachs Group initiated coverage on IDEXX Laboratories in a research note on Friday, October 16th. They issued a "buy" rating and a $740.00 price target on the stock. Nine research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, IDEXX Laboratories has an average rating of "Moderate Buy" and a consensus price target of $727.69.

IDEXX Laboratories Stock Performance

The business has a fifty day moving average of $534.16 and a 200 day moving average of $574.96. The company has a market cap of $45.38 billion, a P/E ratio of 40.50 and a beta of 1.55. The company has a quick ratio of 0.87, a current ratio of 1.17 and a debt-to-equity ratio of 0.19.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share for the quarter, beating the consensus estimate of $3.94 by $0.33. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. The business had revenue of $1.22 billion for the quarter, compared to analysts' expectations of $1.20 billion. During the same quarter in the previous year, the business posted $3.50 earnings per share. The firm's revenue for the quarter was up 9.7% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. On average, equities analysts predict that IDEXX Laboratories, Inc. will post 14.81 EPS for the current year.

Insider Buying and Selling at IDEXX Laboratories

In related news, Director Lawrence D. Kingsley sold 2,203 shares of the business's stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $532.08, for a total transaction of $1,172,172.24. Following the transaction, the director owned 9,568 shares in the company, valued at $5,090,941.44. The trade was a 18.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.79% of the company's stock.

Institutional Trading of IDEXX Laboratories

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Gerber Kawasaki Wealth & Investment Management grew its stake in shares of IDEXX Laboratories by 21.7% during the 3rd quarter. Gerber Kawasaki Wealth & Investment Management now owns 572 shares of the company's stock valued at $299,000 after purchasing an additional 102 shares during the period. Greenfield Seitz Capital Management LLC increased its position in shares of IDEXX Laboratories by 1.2% during the 3rd quarter. Greenfield Seitz Capital Management LLC now owns 4,925 shares of the company's stock valued at $2,572,000 after purchasing an additional 59 shares during the last quarter. Keeler Thomas Management LLC purchased a new stake in shares of IDEXX Laboratories during the 3rd quarter valued at about $925,000. Bell Investment Advisors Inc lifted its stake in shares of IDEXX Laboratories by 45.5% in the 3rd quarter. Bell Investment Advisors Inc now owns 64 shares of the company's stock worth $33,000 after purchasing an additional 20 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in shares of IDEXX Laboratories in the 3rd quarter worth approximately $30,405,000. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc NASDAQ: IDXX develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX's companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.